{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T03:31:29Z","timestamp":1775446289690,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003566","name":"Ministry of Oceans and Fisheries","doi-asserted-by":"publisher","award":["20170305"],"award-info":[{"award-number":["20170305"]}],"id":[{"id":"10.13039\/501100003566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003716","name":"Korea Basic Science Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003716","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"the National Research Foundation of Korea","doi-asserted-by":"crossref","award":["NRF2022R1A5A102641311"],"award-info":[{"award-number":["NRF2022R1A5A102641311"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fibroblast growth factor 21 (FGF21) has pharmaceutical potential against obesity-related metabolic disorders, including non-alcoholic fatty liver disease. Since thermal stability is a desirable factor for therapeutic proteins, we investigated the thermal behavior of human FGF21. FGF21 remained soluble after heating; thus, we examined its temperature-induced structural changes using circular dichroism (CD). FGF21 showed inter-convertible temperature-specific CD spectra. The CD spectrum at 100\u00a0\u00b0C returned to that at 20\u00a0\u00b0C when the heated FGF21 solution was cooled. Through loop swapping, the connecting loop between \u03b210 and \u03b212 in FGF21 was revealed to be associated with the unique thermal behavior of FGF21. According to surface plasmon resonance (SPR) experiments, in vitro cell-based assays, and model high-fat diet (HFD)-induced obesity studies, heated FGF21 maintained biological activities that were comparable to those of non-heated and commercial FGF21s. Based on sequence comparison and structural analysis, five point-mutations were introduced into FGF21. Compared with the wild type, the heated FGF21 variant displayed improved therapeutic potential in terms of body weight loss, the levels of hepatic triglycerides and lipids, and the degree of vacuolization of liver in HFD-fed\u00a0mice.<\/jats:p>","DOI":"10.1038\/s41598-023-27717-x","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T17:04:18Z","timestamp":1674061458000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Heating-mediated purification of active FGF21 and structure-based design of its variant with enhanced potency"],"prefix":"10.1038","volume":"13","author":[{"given":"Ye-Eun","family":"Jung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyeong Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Hyun","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-Woon","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-Gyeong","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeon-Ju","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Bong","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Jun","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyungchan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga Seul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin-Woo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Hee","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun-Kyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyung-Soon","family":"Yim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun-Shin","family":"Cha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"27717_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","volume":"5","author":"Y Xie","year":"2020","unstructured":"Xie, Y. et al. FGF\/FGFR signaling in health and disease. Signal Transduct. Target. Ther. 5, 181 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"27717_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/wdev.176","volume":"4","author":"DM Ornitz","year":"2015","unstructured":"Ornitz, D. M. & Itoh, N. The fibroblast growth factor signaling pathway. WIREs Dev. Biol. 4, 215\u2013266 (2015).","journal-title":"WIREs Dev. Biol."},{"key":"27717_CR3","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1186\/gb-2001-2-3-reviews3005","volume":"2","author":"DM Ornitz","year":"2001","unstructured":"Ornitz, D. M. & Itoh, N. Fibroblast growth factors. Genome Biol. 2, 3005 (2001).","journal-title":"Genome Biol."},{"key":"27717_CR4","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1002\/pro.2175","volume":"21","author":"L Longo","year":"2012","unstructured":"Longo, L., Lee, J. & Blaber, M. Experimental support for the foldability\u2013function tradeoff hypothesis: Segregation of the folding nucleus and functional regions in fibroblast growth factor-1. Protein Sci. 21, 1911\u20131920 (2012).","journal-title":"Protein Sci."},{"key":"27717_CR5","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.tig.2004.08.007","volume":"20","author":"N Itoh","year":"2004","unstructured":"Itoh, N. & Ornitz, D. M. Evolution of the Fgf and Fgfr gene families. Trends Genet. 20, 563\u2013569 (2004).","journal-title":"Trends Genet."},{"key":"27717_CR6","doi-asserted-by":"publisher","first-page":"260","DOI":"10.20892\/j.issn.2095-3941.2015.0102","volume":"13","author":"W-Y Zhou","year":"2016","unstructured":"Zhou, W.-Y., Zheng, H., Du, X.-L. & Yang, J.-L. Characterization of FGFR signaling pathway as therapeutic targets for sarcoma patients. Cancer Biol. Med. 13, 260\u2013268 (2016).","journal-title":"Cancer Biol. Med."},{"key":"27717_CR7","doi-asserted-by":"publisher","first-page":"40061","DOI":"10.1074\/jbc.M112.398826","volume":"287","author":"R Xu","year":"2012","unstructured":"Xu, R. et al. Diversification of the structural determinants of fibroblast growth factor-heparin interactions: Implications for binding specificity*. J. Biol. Chem. 287, 40061\u201340073 (2012).","journal-title":"J. Biol. Chem."},{"key":"27717_CR8","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1128\/MCB.02249-06","volume":"27","author":"R Goetz","year":"2007","unstructured":"Goetz, R. et al. Molecular insights into the Klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol. Cell. Biol. 27, 3417 (2007).","journal-title":"Mol. Cell. Biol."},{"key":"27717_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrd.2015.9","volume":"15","author":"C Degirolamo","year":"2016","unstructured":"Degirolamo, C., Sabb\u00e0, C. & Moschetta, A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat. Rev. Drug Discov. 15, 51\u201369 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"27717_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature25451","volume":"553","author":"G Chen","year":"2018","unstructured":"Chen, G. et al. \u03b1-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. Nature 553, 461\u2013466 (2018).","journal-title":"Nature"},{"key":"27717_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nature25010","volume":"553","author":"S Lee","year":"2018","unstructured":"Lee, S. et al. Structures of \u03b2-klotho reveal a \u2018zip code\u2019-like mechanism for endocrine FGF signalling. Nature 553, 501\u2013505 (2018).","journal-title":"Nature"},{"key":"27717_CR12","doi-asserted-by":"publisher","first-page":"7819","DOI":"10.1073\/pnas.1822055116","volume":"116","author":"ES Kuzina","year":"2019","unstructured":"Kuzina, E. S. et al. Structures of ligand-occupied \u03b2-Klotho complexes reveal a molecular mechanism underlying endocrine FGF specificity and activity. Proc. Natl. Acad. Sci. 116, 7819 (2019).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"27717_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.febslet.2008.11.023","volume":"583","author":"J Yie","year":"2009","unstructured":"Yie, J. et al. FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Lett. 583, 19\u201324 (2009).","journal-title":"FEBS Lett."},{"key":"27717_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/biof.12","volume":"35","author":"H Kurosu","year":"2009","unstructured":"Kurosu, H. & Kuro-o, M. Endocrine fibroblast growth factors as regulators of metabolic homeostasis. BioFactors 35, 52\u201360 (2009).","journal-title":"BioFactors"},{"key":"27717_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41581-018-0078-3","volume":"15","author":"M Kuro-o","year":"2019","unstructured":"Kuro-o, M. The Klotho proteins in health and disease. Nat. Rev. Nephrol. 15, 27\u201344 (2019).","journal-title":"Nat. Rev. Nephrol."},{"key":"27717_CR16","doi-asserted-by":"publisher","first-page":"26687","DOI":"10.1074\/jbc.M704165200","volume":"282","author":"H Kurosu","year":"2007","unstructured":"Kurosu, H. et al. Tissue-specific expression of Klotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282, 26687\u201326695 (2007).","journal-title":"J. Biol. Chem."},{"key":"27717_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jcp.21357","volume":"215","author":"A Kharitonenkov","year":"2008","unstructured":"Kharitonenkov, A. et al. FGF-21\/FGF-21 receptor interaction and activation is determined by \u03b2Klotho. J. Cell. Physiol. 215, 1\u20137 (2008).","journal-title":"J. Cell. Physiol."},{"key":"27717_CR18","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1210\/me.2007-0313","volume":"22","author":"M Suzuki","year":"2008","unstructured":"Suzuki, M. et al. \u03b2Klotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol. Endocrinol. 22, 1006\u20131014 (2008).","journal-title":"Mol. Endocrinol."},{"key":"27717_CR19","doi-asserted-by":"publisher","first-page":"e49977","DOI":"10.1371\/journal.pone.0049977","volume":"7","author":"AC Adams","year":"2012","unstructured":"Adams, A. C., Cheng, C. C., Coskun, T. & Kharitonenkov, A. FGF21 requires \u03b2klotho to act in vivo. PLoS ONE 7, e49977 (2012).","journal-title":"PLoS ONE"},{"key":"27717_CR20","doi-asserted-by":"publisher","first-page":"7432","DOI":"10.1073\/pnas.0701600104","volume":"104","author":"Y Ogawa","year":"2007","unstructured":"Ogawa, Y. et al. \u03b2Klotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl. Acad. Sci. 104, 7432 (2007).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"27717_CR21","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1172\/JCI23606","volume":"115","author":"A Kharitonenkov","year":"2005","unstructured":"Kharitonenkov, A. et al. FGF-21 as a novel metabolic regulator. J. Clin. Investig. 115, 1627\u20131635 (2005).","journal-title":"J. Clin. Investig."},{"key":"27717_CR22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","volume":"23","author":"S Talukdar","year":"2016","unstructured":"Talukdar, S. et al. A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab. 23, 427\u2013440 (2016).","journal-title":"Cell Metab."},{"key":"27717_CR23","doi-asserted-by":"publisher","first-page":"601290","DOI":"10.3389\/fendo.2020.601290","volume":"11","author":"EJ Tillman","year":"2020","unstructured":"Tillman, E. J. & Rolph, T. FGF21: An emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases. Front. Endocrinol. (Lausanne) 11, 601290\u2013601290 (2020).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"27717_CR24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","volume":"18","author":"G Gaich","year":"2013","unstructured":"Gaich, G. et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 18, 333\u2013340 (2013).","journal-title":"Cell Metab."},{"key":"27717_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.tips.2019.12.005","volume":"41","author":"M Zarei","year":"2020","unstructured":"Zarei, M., Pizarro-Delgado, J., Barroso, E., Palomer, X. & V\u00e1zquez-Carrera, M. Targeting FGF21 for the treatment of nonalcoholic steatohepatitis. Trends Pharmacol. Sci. 41, 199\u2013208 (2020).","journal-title":"Trends Pharmacol. Sci."},{"key":"27717_CR26","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.tem.2019.05.007","volume":"30","author":"JE Lewis","year":"2019","unstructured":"Lewis, J. E., Ebling, F. J. P., Samms, R. J. & Tsintzas, K. Going back to the biology of FGF21: New insights. Trends Endocrinol. Metab. 30, 491\u2013504 (2019).","journal-title":"Trends Endocrinol. Metab."},{"key":"27717_CR27","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","volume":"16","author":"L Geng","year":"2020","unstructured":"Geng, L., Lam, K. S. L. & Xu, A. The therapeutic potential of FGF21 in metabolic diseases: From bench to clinic. Nat. Rev. Endocrinol. 16, 654\u2013667 (2020).","journal-title":"Nat. Rev. Endocrinol."},{"key":"27717_CR28","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1042\/BJ20151085","volume":"473","author":"EY Zhen","year":"2016","unstructured":"Zhen, E. Y., Jin, Z., Ackermann, B. L., Thomas, M. K. & Gutierrez, J. A. Circulating FGF21 proteolytic processing mediated by fibroblast activation protein. Biochem. J. 473, 605\u2013614 (2016).","journal-title":"Biochem. J."},{"key":"27717_CR29","doi-asserted-by":"publisher","first-page":"e0151269","DOI":"10.1371\/journal.pone.0151269","volume":"11","author":"AL Coppage","year":"2016","unstructured":"Coppage, A. L. et al. Human FGF-21 is a substrate of fibroblast activation protein. PLoS ONE 11, e0151269 (2016).","journal-title":"PLoS ONE"},{"key":"27717_CR30","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.molmet.2016.07.003","volume":"5","author":"MA S\u00e1nchez-Garrido","year":"2016","unstructured":"S\u00e1nchez-Garrido, M. A. et al. Fibroblast activation protein (FAP) as a novel metabolic target. Mol. Metab. 5, 1015\u20131024 (2016).","journal-title":"Mol. Metab."},{"key":"27717_CR31","doi-asserted-by":"publisher","first-page":"5986","DOI":"10.1074\/jbc.M115.710582","volume":"291","author":"DR Dunshee","year":"2016","unstructured":"Dunshee, D. R. et al. Fibroblast activation protein cleaves and inactivates fibroblast growth factor 21. J. Biol. Chem. 291, 5986\u20135996 (2016).","journal-title":"J. Biol. Chem."},{"key":"27717_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/978-1-4757-2508-7_2","volume-title":"Circular Dichroism and the Conformational Analysis of Biomolecules","year":"1996","unstructured":"Fasman, G. D. (ed.) Circular Dichroism and the Conformational Analysis of Biomolecules 25\u201367 (Springer, 1996)."},{"key":"27717_CR33","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1038\/nprot.2006.204","volume":"1","author":"NJ Greenfield","year":"2006","unstructured":"Greenfield, N. J. Using circular dichroism collected as a function of temperature to determine the thermodynamics of protein unfolding and binding interactions. Nat. Protoc. 1, 2527\u20132535 (2006).","journal-title":"Nat. Protoc."},{"key":"27717_CR34","doi-asserted-by":"publisher","first-page":"14839","DOI":"10.1021\/bi001441y","volume":"39","author":"TD Kim","year":"2000","unstructured":"Kim, T. D., Ryu, H. J., Cho, H. I., Yang, C.-H. & Kim, J. Thermal behavior of proteins: Heat-resistant proteins and their heat-induced secondary structural changes. Biochemistry 39, 14839\u201314846 (2000).","journal-title":"Biochemistry"},{"key":"27717_CR35","doi-asserted-by":"publisher","first-page":"24287","DOI":"10.1016\/S0021-9258(18)54226-5","volume":"266","author":"K Watanabe","year":"1991","unstructured":"Watanabe, K., Chishiro, K., Kitamura, K. & Suzuki, Y. Proline residues responsible for thermostability occur with high frequency in the loop regions of an extremely thermostable oligo-1,6-glucosidase from Bacillus thermoglucosidasius KP1006. J. Biol. Chem. 266, 24287\u201324294 (1991).","journal-title":"J. Biol. Chem."},{"key":"27717_CR36","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3390\/cryst10040256","volume":"10","author":"A Remeeva","year":"2020","unstructured":"Remeeva, A. et al. Effects of proline substitutions on the thermostable LOV domain from Chloroflexus aggregans. Crystals 10, 256 (2020).","journal-title":"Crystals"},{"key":"27717_CR37","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.3390\/molecules25204854","volume":"25","author":"MF Pignataro","year":"2020","unstructured":"Pignataro, M. F., Herrera, M. G. & Dodero, V. I. Evaluation of peptide\/protein self-assembly and aggregation by spectroscopic methods. Molecules 25, 4854 (2020).","journal-title":"Molecules"},{"key":"27717_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/0471140864.ps0607s10","volume":"10","author":"J McCoy","year":"1997","unstructured":"McCoy, J. & La Ville, E. Expression and purification of thioredoxin fusion proteins. Curr. Protoc. Protein Sci. 10, 1\u201314 (1997).","journal-title":"Curr. Protoc. Protein Sci."},{"key":"27717_CR39","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1002\/pro.4150","volume":"30","author":"M Schenkel","year":"2021","unstructured":"Schenkel, M., Treff, A., Deber, C. M., Krainer, G. & Schlierf, M. Heat treatment of thioredoxin fusions increases the purity of \u03b1-helical transmembrane protein constructs. Protein Sci. 30, 1974 (2021).","journal-title":"Protein Sci."},{"key":"27717_CR40","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.addr.2012.09.039","volume":"65","author":"X Chen","year":"2013","unstructured":"Chen, X., Zaro, J. L. & Shen, W.-C. Fusion protein linkers: Property, design and functionality. Adv. Drug Deliv. Rev. 65, 1357\u20131369 (2013).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"27717_CR41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/02648725.2007.10648095","volume":"24","author":"U Nobbmann","year":"2007","unstructured":"Nobbmann, U. et al. Dynamic light scattering as a relative tool for assessing the molecular integrity and stability of monoclonal antibodies. Biotechnol. Genet. Eng. Rev. 24, 117\u2013128 (2007).","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"27717_CR42","doi-asserted-by":"publisher","first-page":"6018","DOI":"10.1210\/en.2008-0816","volume":"149","author":"T Coskun","year":"2008","unstructured":"Coskun, T. et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149, 6018\u20136027 (2008).","journal-title":"Endocrinology"},{"key":"27717_CR43","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2337\/db08-0392","volume":"58","author":"J Xu","year":"2009","unstructured":"Xu, J. et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58, 250\u2013259 (2009).","journal-title":"Diabetes"},{"key":"27717_CR44","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1111\/bph.13499","volume":"173","author":"J Yin","year":"2016","unstructured":"Yin, J. et al. Genetic fusion of human FGF21 to a synthetic polypeptide improves pharmacokinetics and pharmacodynamics in a mouse model of obesity. Br. J. Pharmacol. 173, 2208\u20132223 (2016).","journal-title":"Br. J. Pharmacol."},{"key":"27717_CR45","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.2337\/db20-0209","volume":"69","author":"A Cui","year":"2020","unstructured":"Cui, A. et al. The effects of B1344, a novel fibroblast growth factor 21 analog, on nonalcoholic steatohepatitis in nonhuman primates. Diabetes 69, 1611\u20131623 (2020).","journal-title":"Diabetes"},{"key":"27717_CR46","doi-asserted-by":"publisher","first-page":"6385","DOI":"10.1039\/c2sm25160d","volume":"8","author":"C Forrey","year":"2012","unstructured":"Forrey, C., Douglas, J. F. & Gilson, M. K. The fundamental role of flexibility on the strength of molecular binding. Soft Matter 8, 6385\u20136392 (2012).","journal-title":"Soft Matter"},{"key":"27717_CR47","doi-asserted-by":"publisher","first-page":"11937","DOI":"10.1073\/pnas.0904191106","volume":"106","author":"N Chennamsetty","year":"2009","unstructured":"Chennamsetty, N., Voynov, V., Kayser, V., Helk, B. & Trout, B. L. Design of therapeutic proteins with enhanced stability. Proc. Natl. Acad. Sci. U.S.A. 106, 11937\u201311942 (2009).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"27717_CR48","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3389\/fbioe.2019.00469","volume":"7","author":"X Ren","year":"2020","unstructured":"Ren, X., Zhao, M., Lash, B., Martino, M. M. & Julier, Z. Growth factor engineering strategies for regenerative medicine applications. Front. Bioeng. Biotechnol. 7, 469 (2020).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"27717_CR49","doi-asserted-by":"publisher","first-page":"e58575","DOI":"10.1371\/journal.pone.0058575","volume":"8","author":"A Kharitonenkov","year":"2013","unstructured":"Kharitonenkov, A. et al. Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS ONE 8, e58575 (2013).","journal-title":"PLoS ONE"},{"key":"27717_CR50","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0022-2836(82)90515-0","volume":"157","author":"J Kyte","year":"1982","unstructured":"Kyte, J. & Doolittle, R. F. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157, 105\u2013132 (1982).","journal-title":"J. Mol. Biol."},{"key":"27717_CR51","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.molmet.2018.05.003","volume":"13","author":"A Agrawal","year":"2018","unstructured":"Agrawal, A. et al. Molecular elements in FGF19 and FGF21 defining KLB\/FGFR activity and specificity. Mol. Metab. 13, 45\u201355 (2018).","journal-title":"Mol. Metab."},{"key":"27717_CR52","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/cpim.12","volume":"114","author":"S Paul","year":"2016","unstructured":"Paul, S., Sidney, J., Sette, A. & Peters, B. TepiTool: A pipeline for computational prediction of T cell epitope candidates. Curr. Protoc. Immunol. 114, 11\u201324 (2016).","journal-title":"Curr. Protoc. Immunol."},{"key":"27717_CR53","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.4049\/jimmunol.153.12.5586","volume":"153","author":"A Sette","year":"1994","unstructured":"Sette, A. et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153, 5586\u20135592 (1994).","journal-title":"J. Immunol."},{"issue":"7","key":"27717_CR54","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.4049\/jimmunol.160.7.3363","volume":"160","author":"S Southwood","year":"1998","unstructured":"Southwood, S. et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 160(7), 3363\u20133373 (1998).","journal-title":"J. Immunol."},{"key":"27717_CR55","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1186\/1471-2105-11-568","volume":"11","author":"P Wang","year":"2010","unstructured":"Wang, P. et al. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinform. 11, 568 (2010).","journal-title":"BMC Bioinform."},{"key":"27717_CR56","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/0014-5793(90)80535-Q","volume":"276","author":"AS Kolaskar","year":"1990","unstructured":"Kolaskar, A. S. & Tongaonkar, P. C. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett. 276, 172 (1990).","journal-title":"FEBS Lett."},{"key":"27717_CR57","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1745-7580-2-2","volume":"2","author":"JEP Larsen","year":"2006","unstructured":"Larsen, J. E. P., Lund, O. & Nielsen, M. Improved method for predicting linear B-cell epitopes. Immunome Res. 2, 2\u20132 (2006).","journal-title":"Immunome Res."},{"key":"27717_CR58","doi-asserted-by":"publisher","first-page":"W24","DOI":"10.1093\/nar\/gkx346","volume":"45","author":"MC Jespersen","year":"2017","unstructured":"Jespersen, M. C., Peters, B., Nielsen, M. & Marcatili, P. BepiPred-2.0: Improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res. 45, W24\u2013W29 (2017).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27717-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27717-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27717-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T18:08:19Z","timestamp":1674065299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27717-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["27717"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-27717-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"assertion":[{"value":"25 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1005"}}